Cannabisbasierte Arzneimittel von Avextra
Prescription Medicines, Clinically Developed
Avextra combines innovative, cannabis‑based prescription medicines with a consistent clinical trial program – for more evidence and safety in patient care across Europe.
Our Mission & Vision
Our Mission:
To harness the therapeutic potential of cannabinoids in order to develop, manufacture, and distribute safe, effective, and regulatory‑approved medicines.
Our Vision:
To provide significant relief to patients worldwide who suffer from chronic diseases through natural substances.
RESEaRCH & DEVELOPMENT


What differentiates Avextra from the rest?
- We invest one-third of our total budget in research and development
- We are focused on expanding the evidence base for therapy with cannabis-based medicines
- Ensure the efficacy and quality of our products
- Innovation is part of our DNA


Avextra‘s clinical trials and observational studies
Here you can find out more about Avextra's clinical program and the ongoing studies.


We are Specialists for Plant-Based Medicines
Patients in focus: Patients do not suffer from their illnesses alone but also from the symptoms and burdens of coping with serious illness. The goal of our research is to develop cannabis-based products that have proven effective in relieving symptoms.
VaLUE CHaIN
Complete control over the full value chain
Because cannabis has historically not been cultivated at scale for pharmaceutical production, developing cannabis-based medicines that comply fully with EU quality standards, requires an investment in the full production value chain
Our best guarantee for reliable and secure supply for our pharmaceutical production
EXPERT aREA


Service, Information and Documentation for Healthcare Professionals
Expert Area for Physicians
- Applications and Forms
- scientific publications
Expert Area for Pharmacists
- Availability of Products
- Identity Verification
- Application for prescription
Memberships
VCA - ASSOCIATION OF CANNABIS SUPPLYING PHARMACIES E.V.
The VCA is the professional association for pharmacies supplying cannabis in Germany. It is focused on developing competence, offers further education and promotes the exchange of content between pharmacists, industry, science and politics. The declared goal of the VCA is to ensure an efficient and affordable supply of medical cannabis to patients in Germany.
BPI - FEDERATION OF THE PHARMACEUTICAL INDUSTRY E.V.
The Federation of the Pharmaceutical Industry is the responsible industry association for research-oriented cannabis manufacturers. The BPI also represents the broad spectrum of the pharmaceutical industry on a national and international level. More than 270 companies have joined forces in the BPI.
The EUMCA acts as an authoritative voice of the medical cannabis industry, representing European manufacturers and suppliers of pharmaceutical-grade cannabis products. Its members are a diverse group of stakeholders.
Cooperation Partners
J.W. GOETHE UNIVERSITY FRANKFURT
Avextra Pharma is cooperating with J. W. Goethe University in a preclinical research project. In the future, the scientific findings of this work will help to tailor the composition of cannabis-based products even better to the respective medical indication. In this way, we would like to meet the individual needs of patients in an evidence-based manner.
CESPU
CESPU is a leading institute in Portugal in the field of pharmacy and toxicity. We collaborate on basic toxicology research.
IPS PHARMA
Together with IPS, we operate Integro Medical Cannabis Clinics in Great Britain. This clinic meets the highest quality standards and primarily treats patients with severe pain symptoms.
DGS
With around 4,000 members, the German Society for Pain Medicine is the largest society of practising pain therapists in Europe. Since its foundation in 1984, the medical society has been committed to improving the care of patients with chronic pain. Avextra is a supporting partner in the DGS "Cannabis Initiative 2022 /23" which seeks to improve patient access to Cannabis-based medicines.
















